Start free
← Back to Current Affairs
Current Affairs · 25 October 2026

Ebola vaccine trial begins in DR Congo

UPSCScienceSource: The Hindu – International
1

Why in News

  • The first clinical trial of an Ebola virus disease vaccine in the outbreak gripping the Democratic Republic of Congo began on Friday, October 23, 2026, the World Health Organisation announced.
  • The trial, named Tumaini trial ('hope' in Swahili), began with the first shot of the Ervebo vaccine administered in Bunia, capital of Ituri province, the epicentre of the outbreak.
  • WHO chief Tedros Adhanom Ghebreyesus announced the launch on X, stating the trial will help understand whether vaccine candidates designed for Bundibugyo virus work.
  • The immediate trigger is the DRC's worst-ever Ebola outbreak, which has passed the 9,700-case mark with deaths exceeding 4,600.
  • No approved vaccines or treatments exist for the Bundibugyo species behind the epidemic.
2

What is the issue

  • The epidemic in the DRC is caused by the Bundibugyo species of Ebola virus disease, for which no approved vaccines or treatments exist.
  • Ervebo vaccine, already approved against the more common Zaire strain, is being put through a full-scale human trial in the DRC to see whether it offers cross-protection against Bundibugyo.
  • The Tumaini trial is a single trial framework designed to test the safety, efficacy and immunogenicity of multiple vaccines.
  • It uses a Ring vaccination approach that immunises contacts deemed to be at high risk of infection.
  • Two Bundibugyo-specific candidates are being readied: a ChAdOx1 adenoviral vector jab by the University of Oxford and an mRNA-technology vaccine by the U.S.-based Moderna group.
  • Both candidates are funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
  • The trial will include pregnant women and children aged 12 years and older, generating evidence for populations often excluded from clinical trials.
  • The stakeholders are the WHO, the DRC-led response, CEPI, Oxford, Moderna and affected communities in Ituri.
  • WHO emergencies director Chikwe Ihekweazu said success would be the first clear evidence of vaccine efficacy against Bundibugyo virus, potentially transforming outbreak response and future preparedness.
Detailed analysis

The full analysis is in the app

This page is the summary. The detailed analysis of this story covers:

What is the statusWhat are the challengesWhat measuresWhat lies aheadImportant Data PointsKey conceptsPrevious year questions
Open in Quorum IAS